This invention relates to isolated polypeptides that are long acting analogs of human GLP-1. The disclosed GLP-1 receptor agonist polypeptides have beneficial physicochemical properties relative to endogenous GLP-1 and known synthetic GLP-1 receptor agonist polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t.sub.1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed GLP-1 receptor agonist polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed GLP-1 receptor agonist polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).

This invention relates to the administration of analogs of human amylin for the treatment of type 1 diabetes. Methods described herein augment insulin injection or infusion therapy with separate and continuous co-administration of an amylin analog at a therapeutically effective dose of at least 5 mg per kilogram per day or at a therapeutically effective dose that is equivalent to at least ED70 dose of the amylin analog, as defined herein.

The present invention provides an electrochemical apparatus for monitoring flow rate including a membrane having a space that is formed in a middle portion of the membrane and has a preset volume to contain an ionic fluid, a first electrode and a second electrode provided on both sides of the membrane, and a control unit configured to apply a voltage to the first electrode and the second electrode to change a state of the space to a concentration polarization state, wherein the membrane includes a fluid flow passage through which a fluid flows into and out of the space, and the control unit calculates a flow rate based on an ionic current generated by the fluid injected through the fluid flow passage in the concentration polarization state.

Ferritin or iron-based image enhancement agents identify target tissue for treatment or ablation and are heated by microwave absorption. Microwave heat substrates enhance microwave hyperthermal ablation treatment, and may be percutaneously delivered and imaged by x-ray CT during placement of the microwave treatment antenna, allowing more precise positioning and more complete ablation of a tumor site. One method of treating a target tissue uses image-guided delivery of a heat substrate with a reverse-phase change polymer, and may apply energy to fix a mass of the material in the tissue. The fixed polymer may increase hyperthermia, form a thermal boundary, or blockade a vessel or passage so as to reduce or prevent undesired conductive cooling by contiguous tissue, or may deliver a localized treatment drug at the site, upon heating or as it degrades over time.

The present invention provides methods for treating or suppressing tumor metastasis at a site distinct from the bladder in an individual having a urothelial carcinoma of lower tract, comprising locally delivering to the bladder an effective amount of a chemotherapeutic agent (such as gemcitabine), wherein the chemotherapeutic agent is delivered continuously to the bladder for a sustained period of time (such as at least 24 hours).

This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use.

Embodiments herein relate to an implantable device comprising a casing, a semi-permeable membrane plug at or near a first end of the casing, a piston, beads, and an opening for release of the beads from the implantable device within a body of a human or an animal; wherein the implantable device is configured to be implanted within the body of the human or the animal during delivery of the beads into the body of the human or the animal; wherein the beads comprise a core and a shell with the core being enclosed by the shell and the beads contain a drug; and wherein the implantable device is configured to produce a desired flow rate of elution of the drug from the implantable device when the implantable device is implanted within the body of the human or the animal.

Provided herein is a drug delivery device and composition, such as a particle, comprising conditioned medium. Also provided herein is a method of preparing polymeric particles for release of conditioned medium. Further, a tissue growth scaffold comprising particles for release of conditioned medium is provided.

An oral dosage form of an antidiabetic pharmaceutical composition comprises a core portion, an outer portion, and a controlled membrane film sandwiched therebetween. The core and outer portions respectively comprise a first antidiabetic agent and a second antidiabetic agent, such as metformin HCl and sitagliptin phosphate, each at a therapeutically effective amount. The controlled membrane film encapsulates the core portion and is provided with at least one passageway for allowing the first antidiabetic agent to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form is configured, upon a single-dose oral administration, to provide a maximum plasma concentration of the first antidiabetic agent in the subject from approximately 7.5 to 15 hours after administration. A method for manufacturing the oral dosage form of the antidiabetic pharmaceutical composition is also provided.

Agents, kits, and methods that utilize oxygenation to treat Inflammatory Bowel Disease (IBD) and/or provide prophylaxis against exacerbation of IBD are provided. In several embodiments, the agents, kits, and methods according to several embodiments generate in, or carry to, oxygen in the intestinal lumen to treat IBD and provide prophylaxis against exacerbation of IBD, including those caused by the presence of anaerobic bacteria in the intestine. The agents, kits, and methods provided herein generate an aerobic environment within the intestine to alleviate intestinal inflammation.